Botanix Pharmaceuticals
Botanix Pharmaceuticals, based in Australia, is developing therapies for dermatological illnesses.
The company's pipeline includes treatments for acne, psoriasis and dermatitis. Most of its pipeline incorporates synthesized cannabidiol.
In early 2018, Botanix Pharmaceuticals completed an oversubscribed A$15 million ($11.1 million) investment round.
Latest Botanix Pharmaceuticals News & Features
27 November 2023
26 September 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze